DarnisDMahéJVrignaudBGras-Le GuenCVeyracGJollietP. A report of adverse drug reactions in pediatric emergency medicine. Ann Pharmacother. 2015;49:1298-1304.
2.
BazzanoATMangione-SmithRSchonlauMSuttorpMJBrookRH. Off-label prescribing to children in the United States outpatient setting. Acad Pediatr. 2009;9:81-88.
3.
NevilleKAFrattarelliDAGalinkinJL. Off-label use of drugs in children. Pediatrics. 2014;133:563-567.
4.
DwanKGambleCWilliamsonPRKirkhamJJ. Systematic review of the empirical evidence of study publication bias and outcome reporting bias: an updated review. PLoS One. 2013;8:e66844.
5.
BegleyCGEllisLM. Drug development: raise standards for preclinical cancer research. Nature. 2012;483:531-533.
6.
NuzzoR. How scientists fool themselves—and how they can stop. Nature. 2015;526:182-185.
7.
RuanXKayeAD. Off-label prescribing justified or not? [published online August6, 2015]. Am J Med Qual. doi:10.1177/1062860615599838.
8.
BombardierCLaineLReicinA. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
9.
BresalierRSSandlerRSQuanH. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102.
